2-chloro-N,N-dimethylisonicotinamide, 95.0%, 250mg

(2-Hydroxypyridin-4-yl)boronic acid, 95.0%, 1g

N,N-Diisopropiletilammina (DIPEA), 100 ml, >=99,5%, per sintesi di peptidi, confezione in vetro

2-Bromo-2-(2-nitrophenyl)acetic acid methyl ester, 5g

Ethyl 5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-2-carboxylate, 98%, 1g

5-fluoro-2,4-dimethoxypyrimidine, 25g

(2E)-1-(2,5-dichlorophenyl)-3-(2-ethoxyphenyl)prop-2-en-1-one, 95.0%, 2g

fmoc-b-homo-ser(tbu)-oh, 95.0%, 1g

4-((4-(Trifluoromethyl)phenyl)amino)benzoic acid, 95+%, 1g

Cyclopropanecarbaldehyde, 95.0%, 1g

Methyl3-chloronaphthalene-1-carboxylate, 98%, 100mg

DROXINOSTAT, 98%, 100mg

1-phenyl-1H-pyrazole-4-sulfonamide, 95.0%, 500mg